Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026

RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026, after the market closes on Thursday, November 5, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.

PRNewsWire • 14 hours ago

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 9 hours ago

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Oct 6, 2026

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.

PRNewsWire • Sep 1, 2026

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

Zacks Investment Research • Aug 27, 2026

New Strong Sell Stocks for August 14th

AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.

Zacks Investment Research • Aug 14, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

Amphastar Pharmaceuticals Q2 Earnings Call Highlights

Amphastar Pharmaceuticals NASDAQ: AMPH reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations.

MarketBeat • Aug 6, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.

PRNewsWire • Aug 6, 2026

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.85 per share a year ago.

Zacks Investment Research • Aug 7, 2026